American Board of Psychiatry and Neurology (ABPN) Practice Exam 2025 - Free ABPN Practice Questions and Study Guide

Methylphenidate is typically the first-line medication for treating Attention-Deficit/Hyperactivity Disorder (ADHD) in children due to its established efficacy and favorable safety profile. Methylphenidate works by increasing the levels of neurotransmitters, particularly dopamine and norepinephrine, in the brain, which helps improve attention span, focus, and impulse control.

It has been extensively studied and is recommended in clinical guidelines as the initial pharmacological treatment due to its rapid onset of action and robust evidence supporting its effectiveness in managing ADHD symptoms. This medication is available in various formulations, allowing for personalized treatment approaches based on the specific needs of the child, such as duration of action and side effect profiles.

Other options, while effective in certain contexts, are not considered first-line treatments for ADHD. For instance, Guanfacine may be used in specific situations, especially when addressing behavioral issues or when stimulants are not suitable. Bupropion is not generally recommended as a first-line treatment for ADHD in children, as it is primarily used for depression and smoking cessation. Dextroamphetamine, while effective, is often considered as a second-line option or in specific cases where methylphenidate is not appropriate or effective. This makes